Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.
|
|
- Mark Ward
- 6 years ago
- Views:
Transcription
1 Medical Device Single Audit Program (MDSAP)
2 International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan and the United States of America Representatives of the World Health Organization (WHO) Regulators from the Russian Federation, Mexico, Asian Harmonization Working Party (AHWP) participate as affiliate organization 2
3 IMDRF Work Groups National Competent Authorities Report Exchange Program Roadmap for Implementation of Unique Device Identification system Medical Device Single Audit Program List of Recognized Standards Regulated Product Submission 3
4 MDSAP Goals Recognize Auditing Organizations (AO) Single Audit by AO would: benefit patient health and patient access leverage regulatory resources minimize medical device manufacturing disruptions due to multiple regulatory audits provide global benefit both on short term goals and longer term goals by IMDRF regulators 4
5 MDSAP- Statement of Cooperation (November 2012) Australia Therapeutics Goods Administration (TGA) Brazil Agência Nacional de Vigilância Sanitária (ANVISA) Canada Health Canada/Santé Canada United States of America Food and Drug Administration (FDA) 5
6 MDSAP Manufacturer Audit Criteria GMP requirements of the regulatory authorities One audit to address all Certification will be required Health Canada US FDA Brazilian ANVISA Australian TGA AO Audit 6
7 MDSAP Manufacturer Audit Cycle The initial Audit is followed by a partial Surveillance Audit in each of the following two years and a complete Re-audit, also referred to as a Recertification Audit in the third year Special Audits, Audits Conducted by Regulatory Authorities, and Unannounced Audits are potential extraordinary audits that may occur at any time within the audit cycle. 7
8 How Regulators will use MDSAP reports Australia: The Therapeutics Goods Administration TGA will use an MDSAP audit report as part of the evidence that is assessed for compliance with medical device market authorization requirements unless the medical device is otherwise excluded or exempt from these requirements or if current policies restrict the use of MDSAP audit reports. Brazil: The Brazilian National Health Surveillance Agency ANVISA will utilize the outcomes of the program, including the reports, to constitute an important input on ANVISA s pre-market and post-market assessment procedures, providing, when applicable, key information that are expected to support regulatory technical evaluation on these issues. Canada: Health Canada HC will use a MDSAP audit as part of their Canadian Medical Device Conformity Assessment System (CMDCAS) certification program. Upon the successful conclusion of the pilot, Health Canada's intent is to implement the Medical Device Single Audit Program, as the mechanism to achieve regulatory compliance for quality management system requirements in Canada. 8
9 How Regulators will use MDSAP reports United States: U.S. Food and Drug Administration s Center for Devices and Radiological Health FDA will accept the MDSAP audit reports as a substitute for FDA routine inspections. Inspections conducted "For Cause" or "Compliance Follow-up" by FDA will not be affected by this program. Moreover, this MDSAP program would not apply to any necessary preapproval or post approval inspections for Premarket Approval (PMA) applications or to decisions under section 513(f)(5) of the Act (21 U.S.C. 360c(f)(5)) concerning the classification of a device. Japan s Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) are official observers and active participants in the Pilot Program s Regulatory Authority Council and subject matter expert groups. 9
10 MDSAP Pilot January 1, 2014 Recognition of initial participating Auditing Organizations June 1, 2014 Some Auditing Organizations ready to start auditing medical device manufacturers and more will be added as the pilot progresses. 10
11 Find out more
12 Any Questions 12
Medical Device Single Audit Program (MDSAP)
Medical Device Single Audit Program (MDSAP) Paul Brooks Senior Vice President BSI Healthcare Solutions Copyright 2015 BSI. All rights reserved. 1 Agenda What is MDSAP? How does MDSAP work? I already have
More informationMDSAP Me M dical D e D vice S i S ngle Audit Program
MDSAP Medical Device Single Audit Program Gary Minks VP, Quality & Regulatory Affairs TÜV SÜD America Inc. gminks@tuvam.com Revision: 2013(09(29 TÜV SÜD America 13(04(29 Slide 1 IMDRF International Medical
More informationMedical Device Single Audit Program (MDSAP) Key Points
Medical Device Single Audit Program (MDSAP) Key Points March 2017 Copyright 2016 BSI. All rights reserved. Copyright 2012 BSI. All rights reserved. 1 What is MDSAP? How does MDSAP work? How does MDSAP
More information5 Countries. 1 Unified Audit.
5 Countries. 1 Unified Audit. UNDERSTANDING THE MEDICAL DEVICE SINGLE AUDIT PROGRAM (MDSAP) Melodie Kahl, Mike Wolf, and Scott Edwards July 2017 For more information, please contact: USA Office: + 1 877
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors
More informationCDRH Pilot Activities
CDRH Pilot Activities Cisco Vicenty Program Manager, Case for Quality 1 Office of Compliance, CDRH November 15, 2017 VCIP Voluntary Compliance Improvement Program Pilot Status Description: Assessment:
More informationHosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)
Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information
More informationDITTA CONTRIBUTION TO IMDRF STAKEHOLDER FORUM
DITTA CONTRIBUTION TO IMDRF STAKEHOLDER FORUM Satoshi Kimura DITTA Chair JIRA Executive Director IMDRF Stakeholder Forum Tokyo, 25 Mar. 2015 Key Topics Updates about DITTA DITTA views on current work items
More informationMDSAP AUDIT PROCESS. A Manufacturer s Perspective. Connie Hoy EVP Regulatory Affairs Cynosure, Inc.
MDSAP AUDIT PROCESS A Manufacturer s Perspective Connie Hoy EVP Regulatory Affairs Cynosure, Inc. Cynosure Located in Westford, MA Largest manufacturer of Medical Lasers Second location in Hicksville,
More informationUS FDA and International Regulatory Efforts in Cellular and Gene Therapies
US FDA and International Regulatory Efforts in Cellular and Gene Therapies ISCT Satellite Global Regulatory Perspectives Workshop January 27, 2013 Kimberly Benton, Ph.D. Deputy Director, Division of Cellular
More informationMedical Device Single Audit Program (MDSAP)
Medical Device Single Audit Program (MDSAP) October 2017 Roadshow Copyright 2016 BSI. All rights reserved. Copyright 2012 BSI. All rights reserved. 1 How MDSAP works Timelines and Status Auditing Organization
More informationBrazilian Health Surveillance Agency - Anvisa & Brazilian Pharmacopoeia Global Regulatory Harmonization Opportunities
Agência Nacional de Vigilância Sanitária Anvisa Brazilian Health Surveillance Agency - Anvisa & Brazilian Pharmacopoeia Global Regulatory Harmonization Opportunities Norberto Rech Brazilian Pharmacopoeia
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationMDSAP: CURRENT STATUS AND FUTURE PLANS
MDSAP: CURRENT STATUS AND FUTURE PLANS Seminar hosted by DITTA in conjunction with IMDRF Monday, March 13 2017 Vancouver, BC, Canada A few words about our friend Klaus Stitz: MDSAP: CURRENT STATUS AND
More informationBy: Clay Anselmo COO, DLLS, Founder Reglera and Terry J. Dagnon M.S., Vice President Regulatory Affairs, DLSS
AN INTRODUCTION TO THE WORLDWIDE REGULATORY FRAMEWORK FOR MEDICAL DEVICES By: Clay Anselmo COO, DLLS, Founder Reglera and Terry J. Dagnon M.S., Vice President Regulatory Affairs, DLSS COURSE OUTLINE /
More informationPMDA Perspectives Yoshihiro Matsuda, Ph.D.
PMDA Perspectives Yoshihiro Matsuda, Ph.D. Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency (PMDA) 1 Introduction of PMDA NAME: Pharmaceuticals and Medical Devices
More informationEditor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER
The European Association Medical Devices - Notified Bodies TEAM-NB A.I.S.B.L. Boulevard Frère Orban 35A B 4000 Liège BELGIQUE Tél.: + 32 (0)4 254 55 88 Fax: + 32 (0)4 254 55 89 E-mail: secretary@team-nb.org
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationFINAL DOCUMENT. International Medical Device Regulators Forum. Medical Device Regulatory Audit Reports
FINAL DOCUMENT International Medical Device Regulators Forum Title: Authoring Group: Medical Device Regulatory Audit Reports IMDRF MDSAP Working Group Date: 2 October 2015 Toshiyoshi Tominaga, IMDRF Chair
More informationU.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 st Century Cures Implementation Establish Breakthrough Device Pathway Change
More informationMEDICAL DEVICE GUIDANCE
Effective from 1 January 2013 MEDICAL DEVICE GUIDANCE GN-15: Guidance on Medical Device Product Registration Revision 5 CONTENTS 1. INTRODUCTION... 4 1.1. Scope... 5 1.2. Definitions... 5 2. RISK CLASSIFICATION
More informationNational Health Surveillance Agency. Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017
National Health Surveillance Agency www.anvisa.gov.br Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017 The Board of the National Health Surveillance Agency, in the use of the powers
More informationAbbreviated WHO prequalification assessment procedure
Abbreviated WHO prequalification assessment procedure Industry Briefing on Streamlined WHO Prequalification of Diagnostics Procedure 15/16 May 2014, Geneva Anita Sands Prequalification Team Diagnostics
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationChallenges for further effectiveness
ANVISA and INMETRO Challenges for further effectiveness www.nihonkohden.com Nihon Kohden do Brasil Kotaro Ichikawa Great Improvements Class I & II: From 6 8 to 2 3 months Class III & IV: From 12 18 to
More informationWhite Paper: Improvements to the Australian Regulatory System for Medical Devices. 23 May 2014
White Paper: Improvements to the Australian Regulatory System for Medical Devices 23 May 2014 mtaa.org.au Medical technology for a healthier Australia 0 www.mtaa.org.au Level 12, 54 Miller St, North Sydney
More information2. PMDA provides training program to officials from Thai FDA, Thailand (May 26 to 30)
PMDA Updates June, 2014 Hydrangea macrophylla News 1. Japan Officially Joins PIC/S (May 15 to 16) The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co operation Scheme (PIC/S) Committee
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal
More informationGlobal Medical Device QA/RA Consulting
EmergoGroup.com Global Medical Device QA/RA Consulting More than 2,800 companies trust Emergo to achieve and maintain compliance with global medical device and IVD regulations. Core Areas of Expertise
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationDITTA STANDARDS. What makes a standards a great standard. Industry View. September 2017 Ottawa, Canada
DITTA STANDARDS What makes a standards a great standard Industry View September 2017 Ottawa, Canada Elisabeth George Philips Head of Global Regulations & Standards MEDICAL DEVICE INDUSTRY PERSPECTIVE Introduction
More informationClarifying digital health and software regulation: FDA releases three new guidance documents
Clarifying digital health and software regulation: FDA releases three new guidance documents December 15, 2017 On December 7, 2017, the Food and Drug Administration (FDA or the Agency) released three guidance
More informationProquina A Bayer Company
Proquina A Bayer Company Producing Active Pharmaceutical Ingredients and Advanced Intermediates Proquina ensuring high quality in line with Bayer standards Reliable what we do, we do right As a subsidiary
More informationRegulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance
Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance Nobuo UEMURA Director Office of Medical Devices III Pharmaceuticals and
More informationCollaboration: GS1 and Joint Initiative Council (JIC) in Healthcare
Collaboration: GS1 and Joint Initiative Council (JIC) in Healthcare International Organisation for Standardization European Committee for Standardization Health Level 7 international International Health
More informationCOPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES. Abida Syed M Haq Ministry of Health, Malaysia
COPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES Abida Syed M Haq Ministry of Health, Malaysia Presentation Outline About ASEAN Background Economic Integration Current Scenario Acceptable
More informationINFORMATION ON JAPANESE REGULATORY AFFAIRS
2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationKorean Medical Devices Regulations
Korean Devices Regulations The Ministry of Health and Welfare (MHW) is the healthcare agency having overall responsibility for Devices. The Korea Food and Drug Administration (MFDS), an agency under MHW,
More informationENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ]
ENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ] BEING IN COMPLIANCE HAS NEVER BEEN MORE IMPORTANT Quality encompasses more than meeting regulatory requirements. It extends throughout your organization
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationDevice: Good Manufacturing Practices Manual
Device: Good Manufacturing Practices Manual If searched for a ebook Device: Good Manufacturing Practices Manual in pdf format, then you have come on to loyal site. We present complete variation of this
More informationmechanism. GMP certificates Belén Escribano, PhD Head of the Pharmaceutical Inspection and Enforcement Department of AEMPS
Mutual recognition: basic aspects and mechanism. GMP certificates Belén Escribano, PhD Head of the Pharmaceutical Inspection and Enforcement Department of AEMPS The EU network of medicines agencies 31
More informationState of the Clinical Trials Industry
State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com ix xxxv 1 41 L I S T O F F I G U R E S A N D T A
More informationMedical Devices. The technical requirements also apply when the submitter is not the legal manufacturer 1 (i.e: a distribution company).
UNFPA Technical requirements for medical devices 1. Introduction The following document provides UNFPA s technical requirements in the procurement of medical devices (medical equipment, renewable medical
More informationImplementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan
JCCT workshop on Q8/Q9/Q10 Beijing Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan Yukio HIYAMA Chief, 3 rd Section, Division of Drugs National Institute of Health Sciences, Ministry
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationGlobal Compliance Trends and Warning Letters
Contact: Charles Lu Director, Quality Carlsbad Tech Phone: (760) 431-8284 Fax: (203) 555-0101 5928 Farnsworth Ct Carlsbad, CA, 92008 www.carlsbadtech.com Global Compliance Trends and Warning Letters Governance
More informationUDI: From Compliance to Value OMTEC June 2013 Karen Conway
UDI: From Compliance to Value OMTEC June 2013 Karen Conway 1 GHX GHX proprietary information: Please do not not copy copy or or distribute UDI: The Reality UDI: The Reality UDI: The Reality UDI: The Reality
More informationE2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES
E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES PREPARING FOR E2B(R3) T he electronic transmission of adverse event information to stakeholders, using the International Conference on
More informationHow Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S)
How Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S) ASQ Northeast Pharmaceutical GMP/Quality Conference January
More informationPurchasing Controls. FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015
Purchasing Controls FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015 LCDR Samantha Spindel, Ph.D. Premarket Programs Branch Division of Industry and
More informationRegulatory Affairs - CPS (RGA)
Regulatory Affairs - CPS (RGA) 1 Regulatory Affairs - CPS (RGA) RGA 0502. Principles and Practices of U.S. Regulatory Affairs. 2.5 Offers students an opportunity to prepare for the RAC examination. Uses
More informationCombination Products Part 4 Compliance and Implementation at multi-site Network
Combination Products Part 4 Compliance and Implementation at multi-site Network Vijay Damodaran Eli Lilly & Company September 27, 2017 Contents Key cgmp requirements for combination products How to perform
More informationStrengthening Medical Device Regulatory Capacity in the Americas: working towards regulatory convergence. Alexandre Lemgruber
Strengthening Medical Device Regulatory Capacity in the Americas: working towards regulatory convergence Alexandre Lemgruber Global Harmonization Summit Washington-DC, September 2014 Brief history, important
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationThe Regulated Product Submission: Progress Update
The Regulated Product Submission: Progress Update IMDRF Public Stakeholders Session Sydney, Australia September 25-27, 2012 Mike Ward Chair, IMDRF RPS Working Group IMDRF RPS Proposal Composed of two complementary
More informationIMDRF Project: List of international standards recognized by IMDRF management committee members. Progress Report
List of international standards recognized by IMDRF management committee members Progress Report Dr. Matthias Neumann Federal Ministry of Health, Germany Nice, 19 th of March 213 Mandate: 2 Steps IMDRF
More informationCapacity Building Assistance: Moral Imperative or Common Sense?
Capacity Building Assistance: Moral Imperative or Common Sense? Global Food Safety Policy Forum Washington DC, October 14 th 2009 Paul B Young, PhD Waters Corporation 2008 Waters Corporation Proposals
More informationInstitutional Presentation
Institutional Presentation Mission Statement By keeping operational excellence, we aim to provide the best Service and Technology in supplying chemical products, adding value to clients as well as to employees,
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationUnderstanding GxP Regulations for Healthcare
Understanding GxP Regulations for Healthcare GxP Guidelines What is GxP? GxP is a collection of quality guidelines and regulations created to ensure that bio/pharmaceutical products are safe, meet their
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationTRAINING CATALOG WINTER SPRING 2018
Years of Excellence TRAINING CATALOG WINTER SPRING 2018 Transition Courses NEW! Transition to the New EU Medical Device Regulation (MDR).... 3 NEW! Transition to the Medical Device Single Audit Program
More informationREGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)
REGULATION OF BIOLOGICAL PRODUCTS IN PERU Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) CONTENTS Introduction of DIGEMID Legal Bases of Biological Products
More informationWHO Prequalification of In Vitro Diagnostics Programme
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s Information for Manufacturers on the Manufacturing Site(s) Inspection (Assessment of the Quality Management System) WHO Prequalification
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationTMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team
TMF Reference Model Topline results of 2014 TMF Survey #4 August 2014 Fran Ross TMF Survey Sub-team Trial Master File (TMF) Survey Background TMF Survey purpose: industry-wide, gather insight into quality,
More informationList of participants to the. WHO Chemical Risk Assessment Network
List of participants to the WHO Chemical Risk Assessment Network AFRICAN REGION Botswana, Department of Environmental Health, University of Botswana Botswana, Environmental and Occupational Health Division,
More informationYour Prestigious Partner to reach your business objectives
Medical Devices Project Management, QA/RA, Lean & Support Services Your Prestigious Partner to reach your business objectives This document or any portion thereof shall not be reproduced or used in any
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation
More informationTABLE OF CONTENTS DUPONT TYVEK MEDICAL PACKAGING TRANSITION PROJECT (MPTP) FREQUENTLY ASKED QUESTIONS JUNE 2015 COMMERCIALIZATION 2 5 REGULATORY 6 9
DUPONT TYVEK MEDICAL PACKAGING TRANSITION PROJECT (MPTP) FREQUENTLY ASKED QUESTIONS TABLE OF CONTENTS COMMERCIALIZATION 2 5 REGULATORY 6 9 TECHNICAL 10 12 BACKGROUND 13 15 For more information, including
More informationFINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts
GHTF/SG5/N6:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts Authoring Group: Study Group 5 of the Global Harmonization
More informationMultiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017
Atypical Actives Industry Perspective USP Excipients Stakeholder Forum November 29, 2017 Multiple stakeholders; one objective. Priscilla Zawislak Chair, IPEC-Americas pzawislak@dow.com International Pharmaceutical
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationIn the huge expanse of Asia, Singapore and
New Medical Device Regulation 16 February 2009 By Ames Gross In the huge expanse of Asia, Singapore and Hong Kong are small places. However, after Japan, they are among the most advanced medical markets
More informationAn Introduction to the Worldwide Regulatory Framework for Medical Devices. Elizabeth Malo M.S., Director, Regulatory Affairs
An Introduction to the Worldwide Regulatory Framework for Medical Devices Elizabeth Malo M.S., Director, Regulatory Affairs Course Outline / Agenda» Overview Device Regulatory Framework» US/EU/Canada Premarket
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationRegulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationCanadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines
Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines 1. Introduction The Canadian Cancer Clinical Trials Network (3CTN) will support a portfolio of academic clinical trials
More informationQUALITY INSIGHTS V1/17 THOUGHT LEADERS IN CERTIFICATION AND TECHNICAL CONSULTING
V1/17 QUALITY INSIGHTS THOUGHT LEADERS IN CERTIFICATION AND TECHNICAL CONSULTING UNDERSTANDING THE BENEFITS OF THE NEW ISO 9001 AND ISO 14001 MANAGEMENT SYSTEMS STANDARDS BENEFITS OF CORPORATE TRAINING:
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Ministry of Industry and Trade/ Department of pharmaceutical and medical industry development Moscow September 22, 2017 MEDICINES CIRCULATION SYSTEM IN THE RUSSIAN FEDERATION Ministry of Healthcare Medicines
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationChapter 2 Understanding Bioanalysis Regulations
Chapter 2 Understanding Bioanalysis Regulations Mark Arnold, Eric Fluhler and Boris Gorovits Abstract Bioanalytical data submitted to global health authorities in support of drug approval applications
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationICH Q12: Perspectives on Post-approval
ICH Q12: Perspectives on Post-approval September 6 th 2016 Ciudad de México Renan Gois Health Regulatory Expert Office of Evaluation of Post-approval Changes for Small Molecules Disclaimer This presentation
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationOptimize Your Field Safety Corrective Actions Systems
Optimize Your Field Safety Corrective Actions Systems Patrick Caines, Ph.D. Baxter Healthcare 9 December 2016 1 Agenda International regulatory requirements and expectations for FSCA and recalls Developing
More informationMedidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer
Nano-Tera.ch 05 February 2015 part 8 PMA, 510k, IDE Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 USA/FDA Pre Market Approval System - PMA, Pre Market Notifcation
More informationGS1 Guide on Unique Device Identification (UDI) implementation
GS1 Guide on Unique Device Identification (UDI) implementation This document aims at providing clarification to questions raised by the industry as well as implementation guidance on the use of GS1 standards.
More informationUNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS
UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS Executive Summary European Medicines Agency (EMA) regulations for licensing of medical devices include the use of authorized
More informationIPA Quality Forum Reflections on the Journey so far
IPA Quality Forum Reflections on the Journey so far India Pharmaceutical Forum 2018 23rd Feb 2018 The IPA Quality forum was formed with a vision of helping the Indian pharma industry achieve excellence
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationInternational Leadership Forum on Global Harmonized System Regulatory Implementation around the World. Sponsored by. Practice Specialty
International Leadership Forum on Global Harmonized System Regulatory Implementation around the World Sponsored by Practice Specialty Panel Presentation Outline Introduction of topic : Ashok Garlapati,CSP,QEP,CMIOSH
More information